Ion transport molecules are involved in many physiological and pathological processes.
Among ion transporters, potassium channels show the highest variability and the most frequently altered expression in many tumour types.
Cell cycle and proliferation, cell migration, invasion and apoptosis are all processes that can be modified by the expression of potassium channels.
Permeation-dependent and permeation-independent mechanisms contribute to the roles of potassium channels in oncological processes.
The experience gained with pharmacological manipulation of potassium channels in other pathologies might facilitate the use of potassium channels as cancer targets.
Potassium channels are transmembrane proteins that selectively facilitate the flow of potassium ions down an electrochemical gradient. These molecules have been studied in great detail in the context of cell excitability, but their roles in less cell type-specific functions, such as cell proliferation, angiogenesis or cell migration, have only recently been assessed. Moreover, the importance of these channels for tumour biology has become evident. This, coupled with the fact that they are accessible proteins and that their pharmacology is well characterized, has increased the interest in investigating potassium channels as therapeutic targets in cancer patients.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Wulff, H., Castle, N. A. & Pardo, L. A. Voltage-gated potassium channels as therapeutic targets. Nature Rev. Drug Discov. 8, 982–1001 (2009).
Downie, B. R. et al. Eag1 expression interferes with hypoxia homeostasis and induces angiogenesis in tumors. J. Biol. Chem. 283, 36234–36240 (2008).
Hegle, A. P., Marble, D. D. & Wilson, G. F. A voltage-driven switch for ion-independent signaling by ether-à-go-go K+ channels. Proc. Natl Acad. Sci. USA 103, 2886–2891 (2006).
Gutman, G. A. et al. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol. Rev. 57, 473–508 (2005).
Kaczmarek, L. K. Non-conducting functions of voltage-gated ion channels. Nature Rev. Neurosci. 7, 761–771 (2006). This review brings into focus the non-canonical functions of ion channels as more than just a curious phenomenon and as the biological basis of many functions of ion channels.
Huber, S. M. Oncochannels. Cell Calcium 53, 241–255 (2013).
Choi, M. et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331, 768–772 (2011).
Hofmann, G. et al. HERG K+ channels activation during β1 integrin-mediated adhesion to fibronectin induces an up-regulation of αvβ3 integrin in the preosteoclastic leukemia cell line FLG 29.1. J. Biol. Chem. 276, 4923–4931 (2001).
Munoz, C. et al. Stimulation of HERG channel activity by β-catenin. PLoS ONE 7, e43353 (2012).
Wu, X. et al. p38 MAPK regulates the expression of ether a go-go potassium channel in human osteosarcoma cells. Radiol Oncol. 47, 42–49 (2013).
Alvarez-Baron, C. P., Jonsson, P., Thomas, C., Dryer, S. E. & Williams, C. The two-pore domain potassium channel KCNK5: induction by estrogen receptor α and role in proliferation of breast cancer cells. Mol. Endocrinol. 25, 1326–1336 (2011).
Cho, Y. G. et al. Genetic and expression analysis of the KCNRG gene in hepatocellular carcinomas. Exp. Mol. Med. 38, 247–255 (2006).
Ivanov, D. V. et al. A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3. FEBS Lett. 539, 156–160 (2003).
Usman, H. & Mathew, M. K. Potassium channel regulator KCNRG regulates surface expression of Shaker-type potassium channels. Biochem. Biophys. Res. Commun. 391, 1301–1305 (2010).
Brevet, M. et al. Deregulation of 2 potassium channels in pancreas adenocarcinomas: implication of KV1.3 gene promoter methylation. Pancreas 38, 649–654 (2009).
Brevet, M., Haren, N., Sevestre, H., Merviel, P. & Ouadid-Ahidouch, H. DNA methylation of KV1.3 potassium channel gene promoter is associated with poorly differentiated breast adenocarcinoma. Cell Physiol. Biochem. 24, 25–32 (2009).
Feng, Q. et al. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol. Biomarkers Prev. 17, 645–654 (2008).
Cicek, M. S. et al. Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel. Hum. Mol. Genet. 22, 3038–3047 (2013).
Menendez, S. T. et al. Frequent aberrant expression of the human ether à go-go (hEAG1) potassium channel in head and neck cancer: pathobiological mechanisms and clinical implications. J. Mol. Med. 90, 1173–1184 (2012).
Bianchi, L. et al. herg encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells? Cancer Res. 58, 815–822 (1998). This study shows the first direct evidence of the relevance of a potassium channel for tumour progression in different tumour types.
Cheong, A. et al. Downregulated REST transcription factor is a switch enabling critical potassium channel expression and cell proliferation. Mol. Cell 20, 45–52 (2005).
Lin, H. et al. Transcriptional and post- transcriptional mechanisms for oncogenic overexpression of ether à go-go K+ channel. PLoS ONE 6, e20362 (2011).
Diaz, L. et al. Estrogens and human papilloma virus oncogenes regulate human ether-a-go-go-1 potassium channel expression. Cancer Res. 69, 3300–3307 (2009).
Liu, R. G., Wang, W. J., Song, N., Chen, Y. Q. & Li, L. H. Diazoxide preconditioning alleviates apoptosis of hippocampal neurons induced by anoxia-reoxygenation in vitro through up-regulation of Bcl-2/Bax protein ratio. Sheng Li Xue Bao 58, 345–350 (2006).
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. & Howley, P. M. The E6 oncoprotein encoded by human papillomavirus type-16 and type-18 promotes the degradation of p53. Cell 63, 1129–1136 (1990).
Hwang, S. G., Lee, D. Y., Kim, J. Y., Seo, T. G. & Choe, J. H. Human papillomavirus type 16 E7 binds to E2F1 and activates E2F1-driven transcription in a retinoblastoma protein-independent manner. J. Biol. Chem. 277, 2923–2930 (2002).
Borowiec, A. S. et al. IGF-1 activates hEAG K+ channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation. J. Cell. Physiol. 212, 690–701 (2007).
Sabbatini, P. & McCormick, F. Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis. J. Biol. Chem. 274, 24263–24269 (1999).
Bai, Y. et al. MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-a-go-go (EAG1). Eur. J. Cancer 49, 710–724 (2013).
Yoon, A.-R. et al. MicroRNA-296 is enriched in cancer cells and downregulates p21WAF1 mRNA expression via interaction with its 3′ untranslated region. Nucleic Acids Res. 39, 8078–8091 (2011).
Ousingsawat, J. et al. Expression of voltage-gated potassium channels in human and mouse colonic carcinoma. Clin. Cancer Res. 13, 824–831 (2007).
Pardo, L. A. et al. Oncogenic potential of EAG K+ channels. EMBO J. 18, 5540–5547 (1999).
Ufartes, R. et al. Behavioural and functional characterization of Kv10.1 (Eag1) knockout mice. Hum. Mol. Genet. 22, 2247–2262 (2013).
Martin, S. et al. Eag1 potassium channel immunohistochemistry in the CNS of adult rat and selected regions of human brain. Neuroscience 155, 833–844 (2008).
Hemmerlein, B. et al. Overexpression of Eag1 potassium channels in clinical tumours. Mol. Cancer 5, 41 (2006).
de Queiroz, F. M., Suarez-Kurtz, G., Stühmer, W. & Pardo, L. A. Ether a go-go potassium channel expression in soft tissue sarcoma patients. Mol. Cancer 5, 42 (2006).
Agarwal, J. R., Griesinger, F., Stühmer, W. & Pardo, L. A. The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia. Mol. Cancer 9, 18 (2010).
Asher, V. et al. The Eag potassium channel as a new prognostic marker in ovarian cancer. Diagn. Pathol. 5, 78 (2010).
Ding, X. W., Luo, H. S., Jin, X., Yan, J. J. & Ai, Y. W. Aberrant expression of Eag1 potassium channels in gastric cancer patients and cell lines. Med. Oncol. 24, 345–350 (2007).
Ding, X. W., Yan, J. J., An, P., Lu, P. & Luo, H. S. Aberrant expression of ether a go-go potassium channel in colorectal cancer patients and cell lines. World J. Gastroenterol. 13, 1257–1261 (2007).
Wadhwa, S., Wadhwa, P., Dinda, A. K. & Gupta, N. P. Differential expression of potassium ion channels in human renal cell carcinoma. Int. Urol. Nephrol. 41, 251–257 (2009).
Gómez-Varela, D. et al. Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res. 67, 7343–7349 (2007). This study shows the in vivo efficacy of a functional monoclonal antibody against a potassium channel.
Hartung, F., Stühmer, W. & Pardo, L. A. Tumor cell-selective apoptosis induction through targeting of KV10.1 via bifunctional TRAIL antibody. Mol. Cancer 10, 109 (2011).
Becchetti, A. & Arcangeli, A. Integrins and ion channels in cell migration: implications for neuronal development, wound healing and metastatic spread. Adv. Exp. Med. Biol. 674, 107–123 (2010).
Schwab, A., Fabian, A., Hanley, P. J. & Stock, C. Role of ion channels and transporters in cell migration. Physiol. Rev. 92, 1865–1913 (2012). This is a thorough review of the roles of ion transport molecules in cell migration.
Rezzonico, R. et al. Focal adhesion kinase pp125FAK interacts with the large conductance calcium-activated hSlo potassium channel in human osteoblasts: potential role in mechanotransduction. J. Bone Miner. Res. 18, 1863–1871 (2003).
Wei, J. F. et al. Formation of Kv2.1-FAK complex as a mechanism of FAK activation, cell polarization and enhanced motility. J. Cell. Physiol. 217, 544–557 (2008).
Cheng, L., Yung, A., Covarrubias, M. & Radice, G. L. Cortactin is required for N-cadherin regulation of Kv1.5 channel function. J. Biol. Chem. 286, 20478–20489 (2011).
Hattan, D., Nesti, E., Cachero, T. G. & Morielli, A. D. Tyrosine phosphorylation of Kv1.2 modulates its interaction with the actin-binding protein cortactin. J. Biol. Chem. 277, 38596–38606 (2002).
Bittner, S. et al. The TASK1 channel inhibitor A293 shows efficacy in a mouse model of multiple sclerosis. Exp. Neurol. 238, 149–155 (2012).
Tian, L. et al. A noncanonical SH3 domain binding motif links BK channels to the actin cytoskeleton via the SH3 adapter cortactin. FASEB J. 20, 2588–2590 (2006).
Williams, M. R., Markey, J. C., Doczi, M. A. & Morielli, A. D. An essential role for cortactin in the modulation of the potassium channel Kv1.2. Proc. Natl Acad. Sci. USA 104, 17412–17417 (2007).
Levite, M. et al. Extracellular K+ and opening of voltage-gated potassium channels activate T cell integrin function: Physical and functional association between Kv1.3 channels and β1 integrins. J. Exp. Med. 191, 1167–1176 (2000).
Cherubini, A. et al. Human ether-a-go-go-related gene 1 channels are physically linked to β1 integrins and modulate adhesion-dependent signaling. Mol. Biol. Cell 16, 2972–2983 (2005).
Pillozzi, S. et al. VEGFR-1 (FLT-1), β1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood 110, 1238–1250 (2007).
Pillozzi, S. & Arcangeli, A. Physical and functional interaction between integrins and hERG1 channels in cancer cells. Adv. Exp. Med. Biol. 674, 55–67 (2010).
Li, H. et al. The role of hERG1 K+ channels and a functional link between hERG1 K+ channels and SDF-1 in acute leukemic cell migration. Exp. Cell Res. 315, 2256–2264 (2009).
Afrasiabi, E. et al. Expression and significance of HERG (KCNH2) potassium channels in the regulation of MDA-MB-435S melanoma cell proliferation and migration. Cell Signal 22, 57–64 (2010).
Asghar, M. Y., Viitanen, T., Kemppainen, K. & Tornquist, K. Sphingosine 1-phosphate and human ether-à-go-go-related gene potassium channels modulate migration in human anaplastic thyroid cancer cells. Endocr. Relat. Cancer 19, 667–680 (2012).
Arcangeli, A. et al. A novel inward-rectifying K+ current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells. J. Physiol. 489, 455–471 (1995).
Arcangeli, A. et al. HERG- and IRK-like inward rectifier currents are sequentially expressed during neuronal development of neural crest cells and their derivatives. Eur. J. Neurosci. 9, 2596–2604 (1997).
Pillozzi, S. et al. HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia 16, 1791–1798 (2002).
Smith, G. A. M. et al. Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells. J. Biol. Chem. 277, 18528–18534 (2002).
Lastraioli, E. et al. herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res. 64, 606–611 (2004).
Shao, X. D. et al. Expression and significance of HERG protein in gastric cancer. Cancer Biol. Ther. 7, 45–50 (2008).
Ding, X. W. et al. Prognostic significance of hERG1 expression in gastric cancer. Dig. Dis. Sci. 55, 1004–1010 (2010).
Dolderer, J. H. et al. HERG1 gene expression as a specific tumor marker in colorectal tissues. Ejso 36, 72–77 (2010).
Glassmeier, G. et al. Inhibition of HERG1 K+ channel protein expression decreases cell proliferation of human small cell lung cancer cells. Pflugers Arch. 463, 365–376 (2012).
Menendez, S. T. et al. Role of HERG1 potassium channel in both malignant transformation and disease progression in head and neck carcinomas. Mod. Pathol. 25, 1069–1078 (2012).
Lastraioli, E. et al. hERG1 channels in human esophagus: evidence for their aberrant expression in the malignant progression of Barrett's esophagus. J. Cell. Physiol. 209, 398–404 (2006).
Masi, A. et al. hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br. J. Cancer 93, 781–792 (2005).
Crociani, O. et al. Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells. J. Biol. Chem. 278, 2947–2955 (2003).
Shao, X. D. et al. The potent inhibitory effects of cisapride, a specific blocker for human ether-a-go-go-related gene (HERG) channel, on gastric cancer cells. Cancer Biol. Ther. 4, 295–301 (2005).
Zhao, J., Wei, X. L., Jia, Y. S. & Zheng, J. Q. Silencing of herg gene by shRNA inhibits SH-SY5Y cell growth in vitro and in vivo. Eur. J. Pharmacol. 579, 50–57 (2008).
Vandenberg, J. I. et al. hERG K+ channels: structure, function, and clinical significance. Physiol. Rev. 92, 1393–1478 (2012).
Guasti, L. et al. Identification of a posttranslational mechanism for the regulation of hERG1 K+ channel expression and hERG1 current density in tumor cells. Mol. Cell. Biol. 28, 5043–5060 (2008).
Schwab, A., Hanley, P., Fabian, A. & Stock, C. Potassium channels keep mobile cells on the go. Physiol. (Bethesda) 23, 212–220 (2008).
Schwab, A., Wojnowski, L., Gabriel, K. & Oberleithner, H. Oscillating activity of a Ca2+-sensitive K+ channel. A prerequisite for migration of transformed Madin-Darby canine kidney focus cells. J. Clin. Invest. 93, 1631–1636 (1994).
Reinhardt, J., Golenhofen, N., Pongs, O., Oberleithner, H. & Schwab, A. Migrating transformed mdck cells are able to structurally polarize a voltage-activated K+ channel. Proc. Natl Acad. Sci. USA 95, 5378–5382 (1998).
Schwab, A., Reinhardt, J., Schneider, S. W., Gassner, B. & Schuricht, B. K+ channel-dependent migration of fibroblasts and human melanoma cells. Cell Physiol. Biochem. 9, 126–132 (1999).
Schwab, A., Schuricht, B., Seeger, P., Reinhardt, J. & Dartsch, P. C. Migration of transformed renal epithelial cells is regulated by K+ channel modulation of actin cytoskeleton and cell volume. Pflugers Arch. 438, 330–337 (1999).
Liu, D., Lu, C., Wan, R., Auyeung, W. W. & Mattson, M. P. Activation of mitochondrial ATP-dependent potassium channels protects neurons against ischemia-induced death by a mechanism involving suppression of Bax translocation and cytochrome c release. J. Cereb. Blood Flow Metab. 22, 431–443 (2002).
Ransom, C. B., Liu, X. & Sontheimer, H. BK channels in human glioma cells have enhanced calcium sensitivity. Glia 38, 281–291 (2002).
Weaver, A. K., Liu, X. & Sontheimer, H. Role for calcium-activated potassium channels (BK) in growth control of human malignant glioma cells. J. Neurosci. Res. 78, 224–234 (2004).
Sciaccaluga, M. et al. CXCL12-induced glioblastoma cell migration requires intermediate conductance Ca2+-activated K+ channel activity. Am. J. Physiol. Cell Physiol. 299, C175–C184 (2010).
Catacuzzeno, L., Fioretti, B. & Franciolini, F. Expression and role of the intermediate-conductance calcium-activated potassium channel KCa3.1 in glioblastoma. J. Signal Trans. 2012, 421564 (2012).
Ruggieri, P. et al. The inhibition of KCa3.1 channels activity reduces cell motility in glioblastoma derived cancer stem cells. PLoS ONE 7, e47825 (2012).
Steinle, M. et al. Ionizing radiation induces migration of glioblastoma cells by activating BK K+ channels. Radiother. Oncol. 101, 122–126 (2011). This study shows that, radiotherapy can increase the migration of glioma cells by the activation of potassium channels and it can thus be counterproductive.
Potier, M. et al. Altered SK3/KCa2.3-mediated migration in adenomatous polyposis coli (Apc) mutated mouse colon epithelial cells. Biochem. Biophys. Res. Commun. 397, 42–47 (2010).
Chantome, A. et al. KCa2.3 channel-dependent hyperpolarization increases melanoma cell motility. Exp. Cell Res. 315, 3620–3630 (2009).
Potier, M. et al. Identification of SK3 channel as a new mediator of breast cancer cell migration. Mol. Cancer Ther. 5, 2946–2953 (2006).
Girault, A. et al. New alkyl-lipid blockers of SK3 channels reduce cancer cell migration and occurrence of metastasis. Curr. Cancer Drug Targets 11, 1111–1125 (2011).
Hammadi, M. et al. Human ether a-gogo K+ channel 1 (hEag1) regulates MDA-MB-231 breast cancer cell migration through Orai1-dependent calcium entry. J. Cell. Physiol. 227, 3837–3846 (2012).
Chantome, A. et al. Pivotal role of the lipid raft SK3-Orai1 complex in human cancer cell migration and bone metastases. Cancer Res. 73, 4852–4861 (2013). This study shows the relevance of the coordinated action of a Ca2+ channel and a K+ channel in migration and provides evidence showing that the inhibition of a KCa2.3–ORAI1 complex reduces the number of metastases in vivo.
Hoffmann, E. K. & Pedersen, S. F. Cell volume homeostatic mechanisms: effectors and signalling pathways. Acta Physiol. (Oxf.) 202, 465–485 (2011).
Hoffmann, E. K. Ion channels involved in cell volume regulation: effects on migration, proliferation, and programmed cell death in non adherent EAT cells and adherent ELA cells. Cell Physiol. Biochem. 28, 1061–1078 (2011).
Völkl, H., Paulmichl, M. & Lang, F. Cell volume regulation in renal cortical cells. Ren Physiol. Biochem. 11, 158–173 (1988).
Rouzaire-Dubois, B., Gerard, V. & Dubois, J. M. Involvement of K+ channels in the quercetin-induced inhibition of neuroblastoma cell growth. Pflugers Arch. 423, 202–205 (1993).
Dubois, J.-M. & Rouzaire-Dubois, B. The influence of cell volume changes on tumour cell proliferation. Eur. Biophys. J. 33, 227–232 (2004).
Huang, X. et al. Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes Dev. 26, 1780–1796 (2012). This study gives a mechanistic insight into the consequences of overexpression of a potassium channel for volume control of tumour cells and its relevance for mitosis.
Neylon, C. B., Avdonin, P. V., Larsen, M. A. & Bobik, A. Rat aortic smooth muscle cells expressing charybdotoxin-sensitive potassium channels exhibit enhanced proliferative responses. Clin. Exp. Pharmacol. Physiol. 21, 117–120 (1994).
Wiecha, J. et al. Blockade of Ca2+-activated K+ channels inhibits proliferation of human endothelial cells induced by basic fibroblast growth factor. J. Vasc. Res. 35, 363–371 (1998).
Faehling, M., Koch, E. D., Raithel, J., Trischler, G. & Waltenberger, J. Vascular endothelial growth factor-a activates Ca2+-activated K+ channels in human endothelial cells in culture. Int. J. Biochem. Cell Biol. 33, 337–346 (2001).
Neylon, C. B. Potassium channels and vascular proliferation. Vasc. Pharmacol. 38, 35–41 (2002).
Miguel-Velado, E. et al. Cell cycle-dependent expression of Kv3.4 channels modulates proliferation of human uterine artery smooth muscle cells. Cardiovasc. Res. 86, 383–391 (2010).
Cheong, A. et al. Potent suppression of vascular smooth muscle cell migration and human neointimal hyperplasia by KV1.3 channel blockers. Cardiovasc. Res. 89, 282–289 (2011).
Cidad, P. et al. Kv1.3 channels can modulate cell proliferation during phenotypic switch by an ion-flux independent mechanism. Arterioscler. Thromb. Vasc. Biol. 32, 1299–1307 (2012).
Bi, D. et al. The intermediate-conductance calcium-activated potassium channel KCa3.1 regulates vascular smooth muscle cell proliferation via controlling calcium-dependent signaling. J Biol Chem, 15843–15853 (2013).
Zhao, L. M., Su, X. L., Wang, Y., Li, G. R. & Deng, X. L. KCa3.1 channels mediate the increase of cell migration and proliferation by advanced glycation endproducts in cultured rat vascular smooth muscle cells. Lab. Invest. 93, 159–167 (2013).
Ouadid-Ahidouch, H. et al. Changes in the K+ current-density of MCF-7 cells during progression through the cell cycle: Possible involvement of a h-ether.a-gogo K+ channel. Recept. Channels 7, 345–356 (2001).
Benito, J. et al. Pronounced hypoxia in models of murine and human leukemia: High efficacy of hypoxia-activated prodrug PR-104. PLoS ONE 6, e23108 (2011).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Urrego-Blanco, D., Tomczak, A. P., Zahed, F., Stühmer, W. & Pardo, L. A. Potassium channels in cell cycle and cell proliferation. Philos Trans B (in the press).
DeCoursey, T. E., Chandy, K. G., Gupta, S. & Cahalan, M. D. Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis? Nature 307, 465–468 (1984). This paper describes seminal work on the relevance of potassium channels for cell proliferation.
Blackiston, D. J., McLaughlin, K. A. & Levin, M. Bioelectric controls of cell proliferation: ion channels, membrane voltage and the cell cycle. Cell Cycle 8, 3519–3528 (2009).
Cahalan, M. D. & Chandy, K. G. The functional network of ion channels in T lymphocytes. Immunol. Rev. 231, 59–87 (2009).
Faouzi, M., Chopin, V., Ahidouch, A. & Ouadid-Ahidouch, H. Intermediate Ca2+-sensitive K+ channels are necessary for prolactin-induced proliferation in breast cancer cells. J. Membr. Biol. 234, 47–56 (2010).
Lallet-Daher, H. et al. Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry. Oncogene 28, 1792–1806 (2009).
Prevarskaya, N., Skryma, R. & Shuba, Y. Ion channels and the hallmarks of cancer. Trends Mol. Med. 16, 107–121 (2010).
Skelding, K. A., Rostas, J. A. P. & Verrills, N. M. Controlling the cell cycle: The role of calcium/calmodulin-stimulated protein kinases I and II. Cell Cycle 10, 631–639 (2011).
Kahl, C. R. & Means, A. R. Regulation of cell cycle progression by calcium/calmodulin-dependent pathways. Endocr. Rev. 24, 719–736 (2003).
Patel, A. J. & Lazdunski, M. The 2P-domain K+ channels: role in apoptosis and tumorigenesis. Pflugers Arch. 448, 261–273 (2004).
McFerrin, M. B., Turner, K. L., Cuddapah, V. A. & Sontheimer, H. Differential role of IK and BK potassium channels as mediators of intrinsic and extrinsic apoptotic cell death. Am. J. Physiol. Cell Physiol. 303, C1070–C1078 (2012).
Borjesson, S. I., Englund, U. H., Asif, M. H., Willander, M. & Elinder, F. Intracellular K+ concentration decrease is not obligatory for apoptosis. J. Biol. Chem. 286, 39823–39828 (2011).
Benitez-Rangel, E., Garcia, L., Namorado, M. C., Reyes, J. L. & Guerrero-Hernandez, A. Ion channel inhibitors block caspase activation by mechanisms other than restoring intracellular potassium concentration. Cell Death Dis. 2, e113 (2011).
Nagata, K. et al. Nicorandil inhibits oxidative stress-induced apoptosis in cardiac myocytes through activation of mitochondrial ATP-sensitive potassium channels and a nitrate-like effect. J. Mol. Cell Cardiol 35, 1505–1512 (2003).
Qian, X. et al. Glibenclamide exerts an antitumor activity through reactive oxygen species-c-jun NH2-terminal kinase pathway in human gastric cancer cell line MGC-803. Biochem. Pharmacol. 76, 1705–1715 (2008).
Wang, L. et al. The protective roles of mitochondrial ATP-sensitive potassium channels during hypoxia–ischemia–reperfusion in brain. Neurosci. Lett. 491, 63–67 (2011).
Foster, D. B. et al. Mitochondrial ROMK channel is a molecular component of mitoKATP . Circ. Res. 111, 446–454 (2012).
Kim, Y., Bang, H. & Kim, D. TASK-3, a new member of the tandem pore K+ channel family. J. Biol. Chem. 275, 9340–9347 (2000).
Mu, D. et al. Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell 3, 297–302 (2003).
Lee, G. W. et al. Reduction of breast cancer cell migration via up-regulation of TASK-3 two-pore domain K+ channel. Acta Physiol. (Oxf.) 204, 513–524 (2012).
Pei, L. et al. Oncogenic potential of TASK3 (Kcnk9) depends on K+ channel function. Proc. Natl Acad. Sci. USA 100, 7803–7807 (2003).
Lauritzen, I. et al. K+-dependent cerebellar granule neuron apoptosis. Role of TASK leak K+ channels. J. Biol. Chem. 278, 32068–32076 (2003).
Meuth, S. G. et al. The two-pore domain potassium channel TASK3 functionally impacts glioma cell death. J. Neurooncol 87, 263–270 (2008).
Rusznak, Z. et al. Mitochondrial expression of the two-pore domain TASK-3 channels in malignantly transformed and non-malignant human cells. Virchows Arch. 452, 415–426 (2008).
Innamaa, A. et al. Expression and prognostic significance of the oncogenic K2P potassium channel KCNK9 (TASK-3) in ovarian carcinoma. Anticancer Res. 33, 1401–1408 (2013).
Bock, J., Szabo, I., Jekle, A. & Gulbins, E. Actinomycin D-induced apoptosis involves the potassium channel Kv1.3. Biochem. Biophys. Res. Commun. 295, 526–531 (2002).
Szabo, I. et al. Mitochondrial potassium channel Kv1.3 mediates Bax-induced apoptosis in lymphocytes. Proc. Natl Acad. Sci. USA 105, 14861–14866 (2008). This study highlights the relevance of potassium channels that are expressed in intracellular organelles (and not at the plasma membrane) for fundamental cellular functions.
Gulbins, E., Sassi, N., Grassme, H., Zoratti, M. & Szabo, I. Role of Kv1.3 mitochondrial potassium channel in apoptotic signalling in lymphocytes. Biochim. Biophys. Acta 1797, 1251–1259 (2010).
Leanza, L. et al. Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak-independent death of cancer cells. EMBO Mol. Med. 4, 577–593 (2012).
Leanza, L., Zoratti, M., Gulbins, E. & Szabo, I. Induction of apoptosis in macrophages via Kv1.3 and Kv1.5 potassium channels. Curr. Med. Chem. 19, 5394–5404 (2012).
Sassi, N. et al. An investigation of the occurrence and properties of the mitochondrial intermediate-conductance Ca2+-activated K+ channel mtKCa3.1. Biochim. Biophys. Acta 1797, 1260–1267 (2010).
Pillozzi, S. et al. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood 117, 902–914 (2011). This study gives a strategy for using the targeted inhibition of a potassium channel to overcome resistance to chemotherapeutic agents.
Suzuki, Y. et al. Depolarization potentiates TRAIL-induced apoptosis in human melanoma cells: role for ATP-sensitive K+ channels and endoplasmic reticulum stress. Int. J. Oncol. 41, 465–475 (2012).
Gong, J. H., Liu, X. J., Shang, B. Y., Chen, S. Z. & Zhen, Y. S. HERG K+ channel related chemosensitivity to sparfloxacin in colon cancer cells. Oncol. Rep. 23, 1747–1756 (2010).
Ganapathi, S. B., Kester, M. & Elmslie, K. S. State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy. Am. J. Physiol. Cell Physiol. 296, C701–C710 (2009).
Ortiz, C. S. et al. Eag1 potassium channels as markers of cervical dysplasia. Oncol. Rep. 26, 1377–1383 (2011).
Chen, S. Z., Jiang, M. & Zhen, Y. S. HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin. Cancer Chemother. Pharmacol. 56, 212–220 (2005).
Zhang, R. et al. Human ether-a-go-go-related gene expression is essential for cisplatin to induce apoptosis in human gastric cancer. Oncol. Rep. 27, 433–440 (2012).
Asher, V., Sowter, H., Shaw, R., Bali, A. & Khan, R. Eag and HERG potassium channels as novel therapeutic targets in cancer. World J. Surg. Oncol. 8, 113 (2010).
Sontheimer, H. An unexpected role for ion channels in brain tumor metastasis. Exp. Biol. Med. (Maywood) 233, 779–791 (2008).
Jahchan, N. S. et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discovery http://dx.doi.org/10.1158/2159-8290.CD-13-0183 (2013).
Ninkovic, M., Mitkovski, M., Kohl, T., Stühmer, W. & Pardo, L. A. Physical and functional interaction of KV10.1 with Rabaptin-5 impacts ion channel trafficking. FEBS Lett. 586, 3077–3084 (2012).
Herrmann, S., Ninkovic, M., Kohl, T., Lörinczi, E. & Pardo, L. A. Cortactin controls surface expression of the voltage-gated potassium channel KV10.1. J. Biol. Chem. 287, 44151–44163 (2012).
Farias, L. M. B. et al. Ether à go-go potassium channels as human cervical cancer markers. Cancer Res. 64, 6996–7001 (2004).
The authors thank the Max Planck Society and the past and present members of their department.
L.A.P. and W.S. are shareholders of iOnGen AG.
- Permeation path
The path formed by a fourfold repeat of the pore-forming loop (P-loop) that is provided by each of the four subunits that constitutes the ion channel. Residues in the P-loop are responsible for the selectivity for specific ions.
The induction of apoptotic death in nearby cells, which normally occurs via a death receptor and its ligand. This occurs naturally in the immune system and other systems, and it can also be induced by chimeric ligands.
- Long QT syndrome
The prolongation of the ventricular action potential, which can be diagnosed by a large time interval between the Q and T waves in an electrocardiogram. It is mainly caused by genetic mutations in mechanisms that are responsible for repolarization, such as the Kv11.1-related ion channel ERG.
About this article
Cite this article
Pardo, L., Stühmer, W. The roles of K+ channels in cancer. Nat Rev Cancer 14, 39–48 (2014). https://doi.org/10.1038/nrc3635
Pharmacological modulation of Kv1.3 potassium channel selectively triggers pathological B lymphocyte apoptosis in vivo in a genetic CLL model
Journal of Experimental & Clinical Cancer Research (2022)
EAG1 enhances hepatocellular carcinoma proliferation by modulating SKP2 and metastasis through pseudopod formation
Influence of Kv11.1 (hERG1) K+ channel expression on DNA damage induced by the genotoxic agent methyl methanesulfonate
Pflügers Archiv - European Journal of Physiology (2021)
Scientific Reports (2020)